

Recent data on melanoma immunotherapy

26 November 2020 | Program: 14:30–15:35 (65 minutes)
Online Meeting, Central and South-East European Melanoma Expert Group (CSEEMEG) regional meeting

14:30–14:45	Adjuvant nivolumab vs ipilimumab in resected stage III/IV melanoma: 4-year recurrence-free and overall survival results from CheckMate 238 Prof. dr. Željko Mijušković
14:45–15:00	Dosing and administration and management of adverse events Dr. Suzana Matković
15:00–15:15	Survival outcomes and characterization of complete responses in metastatic melanoma (CheckMate 067, pooled CheckMate 066, 067, 069 respectively) Prof. dr. Nada Babović (Chair)
15:15–15:30	First-line immunotherapy with nivolumab plus ipilimumab versus targeted therapy with BRAF plus MEK inhibitors in patients with BRAF-mutant advanced melanoma: a real-world analysis Prof dr. Lidija Kandolf Sekulovic (Chair)
15:30–15:35	Summary and Q&A
